Jan 26, 2020 Audentes Therapeutics Announces Plans to Build New State-of-the-Art Gene Therapy Manufacturing Facility in Sanford, North Carolina. View All News >. @audentestx. Audentes is different – we take time to understand our patient communities and weave that knowledge with our scientific insights Find the latest Audentes Therapeutics, Inc. (BOLD) stock quote, history, news and other vital information to help you with your stock trading and investing. Jan 14, 2020 Get breaking news and analysis on Audentes Therapeutics, Inc. (BOLD) stock, price quote and chart, trading and investing tools. Dec 3, 2019 Shares more than doubled after the gene therapy company announced that it has accepted a buyout offer. Here are the key details. Dec 2, 2019 Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic any obligation to revise or update any forward-looking statements to
Jan 15, 2020 The information contained in this document is provided only as of the date hereof, and no party undertakes any obligation to revise or update any
Audentes Therapeutics Announces Plans to Build New State-of-the-Art Gene Therapy Manufacturing Facility in Sanford, North Carolina - Audentes plans to invest over $100 million and create over 200 Most relevant news about AUDENTES THERAPEUTICS, INC: 11/07: AUDENTES THERAPEUTICS: 3Q Earnings Snapshot: AQ. 11/07: AUDENTES THERAPEUTICS: Reports Third Quarter 2019 Financial Results and Provide.. BU. 10/31: AUDENTES THERAPEUTICS: to Release Third Quarter 2019 Financial Results and Prov.. BU. About Audentes Therapeutics, Inc. Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious Audentes Therapeutics earned a news impact score of 1.6 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Audentes Therapeutics.
Audentes Therapeutics's top competitors are Sanofi Genzyme, Amicus Therapeutics and Valerion Therapeutics. See Audentes Therapeutics's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform.
Audentes Therapeutics is a biotechnology company committed to the development and Their latest funding was raised on Oct 13, 2015 from a Series C round. » More brands of Audentes Therapeutics, Inc. Summary · Quotes · Charts · News Dec 4, 2019 agreed to acquire genetic medicines company Audentes Therapeutics for a total News. Astellas to acquire Audentes Therapeutics for $3bn. Feb 19, 2020 Astellas company Audentes Therapeutics has unveiled plans to construct a new gene therapy manufacturing facility in Sanford, North Carolina, View Audentes Therapeutics Inc (www.audentestx.com) location in California, United States , revenue, industry and description. Find related and similar Jan 16, 2020 Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned Dec 3, 2019 Astellas shares down 1.1% in Tokyo. TOKYO, Dec 3- Japan's Astellas Pharma Inc is buying U.S. drugmaker Audentes Therapeutics Inc for
Here's the most recent news related to Audentes Therapeutics. Skip to main content. Twitter LinkedIn. Search. Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
$BOLD NEW ARTICLE : Paul Tudor Jones' Firm Buys Caesars Entertainment, Audentes Therapeutics dashboard.stck.pro/news.php Get all the latest $BOLD
Apr 8, 2019 Audentes aims to create new gene therapies for two forms of muscular dystrophy: Duchenne and myotonic muscular dystrophy.
SANFORD -- North Carolina scored another major win today in the gene therapy leadership race. Audentes Therapeutics, a San Francisco-based gene therapy company, Audentes Therapeutics, an Astellas company focused on developing innovative AAV-based genetic medicines, announced today that it plans to invest $109 million to build a new 135,000 square foot Audentes Therapeutics plans to submit an investigational new drug (IND) application for its Pompe disease gene therapy AT845 this year. In a recent update, Audentes, a biotech company, discussed its portfolio of investigational gene therapies for rare diseases.